PIK3CA and ovarian carcinoma: Although some previous studies demonstrated the increased levels of p21 and p27 cyclin-dependent kinase inhibitors [32], several recent studies with ovarian cancer cells [31, 33] reported the decreased expression of p21 and p27 by PI3K inhibitor LY-294002 treatment, which were consistent with our results.